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Abstract
Aims/hypothesis To assess whether self-monitoring of
blood glucose (SMBG) is an independent predictor of
improved outcome in a community-based cohort of type 2
diabetic patients.
Materials and methods We used longitudinal data from (1)
1,280 type 2 diabetic participants in the observational
Fremantle Diabetes Study (FDS) who reported SMBG and
diabetes treatment status at study entry (1993–1996), and
(2) a subset of 531 participants who attended six or more
annual assessments (referred to as the 5-year cohort).
Diabetes-related morbidity, cardiac death and all-cause
mortality were ascertained at each assessment, supple-
mented by linkage to the Western Australian Data Linkage
System.
Results At baseline, 70.2% (898 out of 1,280) of type 2
patients used SMBG. During 12,491 patient-years of
follow-up (mean 9.8±3.5 years), 486 (38.0%) type 2
participants died (196 [15.3%] from cardiac causes). SMBG
was significantly less prevalent in those who died during
follow-up than in those who were still alive at the end of
June 2006 (65.4 vs 73.0%, p=0.005). In Cox proportional
hazards modelling, after adjustment for confounding and
explanatory variables, SMBG was not independently
associated with all-cause mortality, but was associated with
a 79% increased risk of cardiovascular mortality in patients
not treated with insulin. For the 5-year cohort, time-
dependent SMBG was independently associated with a
48% reduced risk of retinopathy.
Conclusions/interpretation SMBG was not independently
associated with improved survival. Inconsistent findings
relating to the association of SMBG with cardiac death and
retinopathy may be due to confounding, incomplete
covariate adjustment or chance.
Keywords Cohortstudy.Epidemiology.Outcomes.
Self-monitoringofbloodglucose.Type2diabetes
Abbreviations
ACR urinary albumin:creatinine ratio
CVD cerebrovascular disease
FDS Fremantle Diabetes Study
HR hazard ratio
ICD International Classification of Diseases
OHA oral hypoglycaemic agent
PAD peripheral arterial disease
ROSSO Retrolective Study ‘Self-monitoring of Blood
Glucose and Outcome in Patients with Type 2
Diabetes’
SMBG self-monitoring of blood glucose
WADLS Western Australian Data Linkage System
Introduction
Intensive glycaemic control is a cost-effective way of
reducing the complications associated with type 2 diabetes
[1]. Whether self-monitoring of blood glucose (SMBG) can
improve glycaemia is subject to debate [2, 3]. The
Retrolective Study ‘Self-monitoring of Blood Glucose and
Outcome in Patients with Type 2 Diabetes’ (ROSSO)
investigators recently reported that SMBG was associated
with decreased diabetes-related morbidity and all-cause
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e-mail: wdavis@cyllene.uwa.edu.aumortality in type 2 diabetes, despite the SMBG group
having a higher mean baseline fasting plasma glucose than
the non-SMBG group [4]. In an Australian community-
based cohort of type 2 patients we found that SMBG was
not a determinant of glycaemic control [5], and now
investigate whether, as in ROSSO, those who performed
SMBG had better outcomes than those who did not.
Subjects and methods
Subjects The Fremantle Diabetes Study (FDS) was a
longitudinal observational study in a community of
120,097 people in the state of Western Australia. We
identified 2,258 subjects between 1993 and 1996, using all
available sources, and recruited 1,426 (63%) to attend
annual assessments, of whom 1,294 (91%) had type 2
diabetes [6]. The FDS protocol was approved by the
Fremantle Hospital Human Rights Committee and all
subjects gave informed consent. The present study included
(1) 1,280 type 2 patients (mean age 64.1±11.3 years, 48.8%
men) with complete diabetes treatment and mortality data
who reported SMBG status at FDS entry, and (2) a subset
of 531 patients (mean age 62.4±9.4 years, 54.2% men) who
attended six or more consecutive annual assessments.
Clinical assessment At baseline and annual reviews, a
comprehensive history was taken and a physical examina-
tion was performed. Complications were identified using
standard criteria [5, 7]. Microalbuminuria was defined as an
urinary albumin:creatinine ratio (ACR) ≥3.0 mg/mmol on a
first morning sample, neuropathy as a score >2/8 on the
clinical portion of the Michigan Neuropathy Screening
Instrument, and retinopathy as any grade in one/both eyes
on direct and/or indirect ophthalmoscopy and/or detailed
specialist assessment. Self-report and hospitalisations were
used to identify cerebrovascular disease (CVD; stroke,
transient ischaemic attack) and CHD (myocardial infarc-
tion, angina, coronary revascularisation). Peripheral arterial
disease (PAD) was defined as an ankle:brachial index ≤0.9
or diabetes-related amputation. Blindness in one or both
eyes, foot amputation and end-stage renal disease were also
defined to allow comparison with the ROSSO findings [4].
Hospital morbidity and mortality Western Australian gov-
ernment registers record details of all deaths and hospital
admissions, and make up part of the Western Australian Data
Linkage System (WADLS) [8], which provided endpoint
data to the end of June 2006. The Confidentiality of Health
Information Committee approved linkage with the FDS
database. All hospitalisations for endpoints were identified
using the International Classification of Diseases (ICD)-9-
CM and ICD-10-AM diagnosis/procedure codes. Causes of
death were classified independently by two authors (D.G.
Bruce, T.M.E. Davis) as ‘cardiac’ or ‘other’ [7].
Statistical analysis Data were analysed using SPSS for
Windows (version 11.5) and are presented as proportions
or means±SD. Comparison of two independent propor-
tions was by Fisher’s exact test. Freedom from non-fatal
endpoints, all-cause mortality or cardiac death was
analysed by baseline SMBG status using the Kaplan–
Meier method and compared with the log-rank test. For
outcomes with sufficient events, Cox proportional hazards
modelling (forward conditional variable entry and removal
with p<0.05 and p>0.05, respectively), was used to
determine: (1) independent predictors of first ever occur-
rence of endpoints, with all clinically plausible univariate
variables with a p value of less than 0.20 considered for
entry; and (2) whether, after adjusting for these variables,
either SMBG at baseline or the time-dependent covariate
SMBG was independently associated with outcome. A p
value of less than 0.05 was considered significant.
Results
At baseline, 898 type 2 patients (70.2%) performed
SMBG. During 12,491 patient-years of follow-up (mean
9.8±3.5 years), 486 (38.0%) died, of which 196 (15.3%)
deaths were from cardiac causes. SMBG was significantly
less prevalent in those who died during follow-up than in
those who were alive at the end of June 2006 (65.4 vs
73.0%, p=0.005).
SMBG and mortality In unadjusted survival analysis
(Model 1), SMBG was associated with a significant 24%
reduction in all-cause mortality (Table 1). After adjusting
for age, sex and diabetes duration (Model 2), this became a
non-significant 11% increased risk. Additional adjustment
for independent risk factors for all-cause mortality (Model
3) did not alter this finding. In patients on diet±oral
hypoglycaemic agents (OHAs) and in those on insulin,
baseline SMBG was associated with significant unadjusted
24% and 54% reductions in the risk of death, respectively,
which became non-significant after full adjustment.
In unadjusted models for cardiac death, there was a
significant 55% risk reduction in insulin-treated patients
(Table 1); after full adjustment, this became non-significant.
SMBG was associated with a 55% increased risk of cardiac
death in Model 3 as a result of a significant 79% increased
risk in patients not treated with insulin.
Five-year cohort Consistent with intensification of diabetes
therapy, and as reported previously [5], the proportion of
Diabetologia (2007) 50:510–515 511T
a
b
l
e
1
H
a
z
a
r
d
r
a
t
i
o
s
f
o
r
a
l
l
-
c
a
u
s
e
a
n
d
c
a
r
d
i
a
c
m
o
r
t
a
l
i
t
y
i
n
1
,
2
8
0
t
y
p
e
2
d
i
a
b
e
t
e
s
p
a
t
i
e
n
t
s
b
y
S
M
B
G
s
t
a
t
u
s
f
o
r
:
(
1
)
a
l
l
d
i
a
b
e
t
e
s
t
r
e
a
t
m
e
n
t
t
y
p
e
s
;
(
2
)
t
h
o
s
e
w
h
o
w
e
r
e
t
r
e
a
t
e
d
b
y
d
i
e
t
w
i
t
h
o
r
w
i
t
h
o
u
t
O
H
A
s
;
a
n
d
(
3
)
t
h
o
s
e
t
a
k
i
n
g
i
n
s
u
l
i
n
w
i
t
h
o
r
w
i
t
h
o
u
t
O
H
A
s
N
o
S
M
B
G
S
M
B
G
N
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
N
u
m
b
e
r
o
f
e
v
e
n
t
s
A
b
s
o
l
u
t
e
r
i
s
k
a
N
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
N
u
m
b
e
r
o
f
e
v
e
n
t
s
A
b
s
o
l
u
t
e
r
i
s
k
a
L
o
g
-
r
a
n
k
p
v
a
l
u
e
H
R
(
9
5
%
C
I
)
A
l
l
p
a
t
i
e
n
t
s
A
l
l
-
c
a
u
s
e
m
o
r
t
a
l
i
t
y
M
o
d
e
l
1
(
u
n
a
d
j
u
s
t
e
d
)
3
8
2
1
6
8
4
6
.
7
8
9
8
3
1
8
3
5
.
8
0
.
0
0
4
0
.
7
6
(
0
.
6
3
–
0
.
9
2
)
M
o
d
e
l
2
(
a
d
j
u
s
t
e
d
)
b
1
.
1
1
(
0
.
9
2
–
1
.
3
5
)
M
o
d
e
l
3
(
a
d
j
u
s
t
e
d
)
c
1
.
1
5
(
0
.
9
3
–
1
.
4
4
)
C
a
r
d
i
a
c
m
o
r
t
a
l
i
t
y
M
o
d
e
l
1
(
u
n
a
d
j
u
s
t
e
d
)
3
8
2
6
1
1
7
.
0
8
9
8
1
3
5
1
5
.
2
0
.
4
6
0
.
8
9
(
0
.
6
6
–
1
.
2
1
)
M
o
d
e
l
2
(
a
d
j
u
s
t
e
d
)
b
1
.
3
5
(
0
.
9
9
–
1
.
8
6
)
M
o
d
e
l
3
(
a
d
j
u
s
t
e
d
)
d
1
.
5
5
(
1
.
0
7
–
2
.
2
4
)
D
i
e
t
±
O
H
A
s
A
l
l
-
c
a
u
s
e
m
o
r
t
a
l
i
t
y
M
o
d
e
l
1
(
u
n
a
d
j
u
s
t
e
d
)
3
5
4
1
4
5
4
2
.
6
7
7
3
2
5
2
3
2
.
5
0
.
0
0
8
0
.
7
6
(
0
.
6
2
–
0
.
9
3
)
M
o
d
e
l
2
(
a
d
j
u
s
t
e
d
)
b
1
.
1
5
(
0
.
9
3
–
1
.
4
3
)
M
o
d
e
l
3
(
a
d
j
u
s
t
e
d
)
e
1
.
2
0
(
0
.
9
4
–
1
.
5
2
)
C
a
r
d
i
a
c
m
o
r
t
a
l
i
t
y
M
o
d
e
l
1
(
u
n
a
d
j
u
s
t
e
d
)
3
5
4
5
1
1
5
.
0
7
7
3
1
0
8
1
3
.
9
0
.
6
5
0
.
9
3
(
0
.
6
6
–
1
.
2
9
)
M
o
d
e
l
2
(
a
d
j
u
s
t
e
d
)
b
1
.
5
1
(
1
.
0
6
–
2
.
1
4
)
M
o
d
e
l
3
(
a
d
j
u
s
t
e
d
)
f
1
.
7
9
(
1
.
1
9
–
2
.
6
9
)
I
n
s
u
l
i
n
±
O
H
A
s
A
l
l
-
c
a
u
s
e
m
o
r
t
a
l
i
t
y
M
o
d
e
l
1
(
u
n
a
d
j
u
s
t
e
d
)
2
8
2
3
1
1
9
.
3
1
2
5
6
6
5
8
.
4
0
.
0
0
1
0
.
4
6
(
0
.
2
9
–
0
.
7
5
)
M
o
d
e
l
2
(
a
d
j
u
s
t
e
d
)
b
0
.
6
8
(
0
.
4
1
–
1
.
1
4
)
M
o
d
e
l
3
(
a
d
j
u
s
t
e
d
)
g
0
.
7
3
(
0
.
4
3
–
1
.
2
6
)
C
a
r
d
i
a
c
m
o
r
t
a
l
i
t
y
M
o
d
e
l
1
(
u
n
a
d
j
u
s
t
e
d
)
2
8
1
0
5
1
.
9
1
2
5
2
7
2
3
.
9
0
.
0
2
6
0
.
4
5
(
0
.
2
2
–
0
.
9
3
)
M
o
d
e
l
2
(
a
d
j
u
s
t
e
d
)
b
0
.
5
8
(
0
.
2
7
–
1
.
2
7
)
M
o
d
e
l
3
(
a
d
j
u
s
t
e
d
)
h
0
.
5
2
(
0
.
2
2
–
1
.
1
9
)
a
E
v
e
n
t
s
p
e
r
1
,
0
0
0
p
e
r
s
o
n
–
y
e
a
r
s
b
M
o
d
e
l
2
i
n
c
l
u
d
e
s
a
g
e
,
s
e
x
a
n
d
d
u
r
a
t
i
o
n
o
f
d
i
a
b
e
t
e
s
i
n
e
a
c
h
c
a
s
e
.
M
o
d
e
l
3
i
n
c
l
u
d
e
s
a
l
l
v
a
r
i
a
b
l
e
s
i
n
M
o
d
e
l
2
,
p
l
u
s
:
c
p
r
i
o
r
C
H
D
,
C
V
D
,
P
A
D
,
n
e
u
r
o
p
a
t
h
y
,
r
e
t
i
n
o
p
a
t
h
y
,
l
n
[
A
C
R
]
,
a
n
y
e
x
e
r
c
i
s
e
i
n
p
a
s
t
2
w
e
e
k
s
(
n
e
g
a
t
i
v
e
)
,
a
b
d
o
m
i
n
a
l
o
b
e
s
i
t
y
(
n
e
g
a
t
i
v
e
)
,
o
n
l
i
p
i
d
-
l
o
w
e
r
i
n
g
m
e
d
i
c
a
t
i
o
n
s
(
n
e
g
a
t
i
v
e
)
,
A
u
s
t
r
a
l
i
a
n
A
b
o
r
i
g
i
n
a
l
,
A
s
i
a
n
(
n
e
g
a
t
i
v
e
)
,
c
u
r
r
e
n
t
s
m
o
k
e
r
d
p
r
i
o
r
C
H
D
,
C
V
D
,
P
A
D
,
n
e
u
r
o
p
a
t
h
y
,
r
e
t
i
n
o
p
a
t
h
y
,
l
n
[
A
C
R
]
,
s
y
s
t
o
l
i
c
B
P
(
n
e
g
a
t
i
v
e
)
,
t
o
t
a
l
s
e
r
u
m
c
h
o
l
e
s
t
e
r
o
l
,
A
u
s
t
r
a
l
i
a
n
A
b
o
r
i
g
i
n
a
l
,
c
u
r
r
e
n
t
s
m
o
k
e
r
e
p
r
i
o
r
C
H
D
,
C
V
D
,
P
A
D
,
n
e
u
r
o
p
a
t
h
y
,
r
e
t
i
n
o
p
a
t
h
y
,
l
n
[
A
C
R
]
,
a
b
d
o
m
i
n
a
l
o
b
e
s
i
t
y
(
n
e
g
a
t
i
v
e
)
,
o
n
l
i
p
i
d
-
l
o
w
e
r
i
n
g
m
e
d
i
c
a
t
i
o
n
(
n
e
g
a
t
i
v
e
)
,
A
u
s
t
r
a
l
i
a
n
A
b
o
r
i
g
i
n
a
l
,
c
u
r
r
e
n
t
s
m
o
k
e
r
f
p
r
i
o
r
C
H
D
,
P
A
D
,
n
e
u
r
o
p
a
t
h
y
,
r
e
t
i
n
o
p
a
t
h
y
,
l
n
[
A
C
R
]
,
s
y
s
t
o
l
i
c
B
P
(
n
e
g
a
t
i
v
e
)
,
t
o
t
a
l
s
e
r
u
m
c
h
o
l
e
s
t
e
r
o
l
,
c
u
r
r
e
n
t
s
m
o
k
e
r
g
p
r
i
o
r
C
H
D
,
d
i
a
b
e
t
e
s
e
d
u
c
a
t
i
o
n
(
e
v
e
r
;
n
e
g
a
t
i
v
e
)
,
H
b
A
1
c
,
A
u
s
t
r
a
l
i
a
n
A
b
o
r
i
g
i
n
a
l
h
p
r
i
o
r
C
H
D
,
r
e
t
i
n
o
p
a
t
h
y
,
H
b
A
1
c
,
A
u
s
t
r
a
l
i
a
n
A
b
o
r
i
g
i
n
a
l
512 Diabetologia (2007) 50:510–515the 5-year longitudinal cohort using SMBG increased over
a mean of 5.4±0.5 years, from 75.2% at entry to 85.5% at
third review, with little change thereafter.
We ascertained the incidence of first ever occurrence
of micro- and macrovascular complications by baseline
SMBG status (Table 2). Unadjusted survival analysis
Table 2 Hazard ratios of first-ever non-fatal complications in the 531 type 2 diabetes patients in the longitudinal arm for single and combined
micro- and macrovascular events, and the ROSSO Study non-fatal endpoint, by SMBG status at: (1) baseline; and (2) each annual assessment
(time-dependent covariate)
No SMBG at baseline SMBG at baseline Time-dependent
SMBG use
No. of
patients
No. of
events
Absolute
risk
a
No. of
patients
No. of
events
Absolute
risk
a
Log-rank
p value
HR (95% CI) HR (95% CI)
Retinopathy
Model 1 (unadjusted) 116 47 90.0 349 112 68.4 0.11 0.76 (0.54–1.07) 0.51 (0.36–0.72)
Model 2 (adjusted)
b 0.80 (0.57–1.13) 0.52 (0.37–0.74)
Model 3 (adjusted)
c 0.82 (0.58–1.16) 0.52 (0.37–0.73)
Neuropathy
Model 1 (unadjusted) 84 62 199.3 256 186 203.0 0.76 1.05 (0.78–1.40) 0.77 (0.57–1.03)
Model 2 (adjusted)
b 1.16 (0.87–1.55) 0.79 (0.59–1.07)
Model 3 (adjusted)
d 1.30 (0.97–1.74) 0.89 (0.66–1.20)
Microalbuminuria
Model 1 (unadjusted) 82 37 104.1 258 103 90.6 0.38 0.85 (0.58–1.23) 0.77 (0.52–1.14)
Model 2 (adjusted)
b 0.88 (0.60–1.28) 0.78 (0.53–1.15)
Model 3 (adjusted)
e 0.91 (0.62–1.33) 0.74 (0.50–1.10)
Any microangiopathy
Model 1 (unadjusted) 58 50 280.5 172 153 302.6 0.59 1.09 (0.79–1.51) 0.99 (0.71–1.38)
Model 2 (adjusted)
b 1.22 (0.89–1.68) 0.96 (0.69–1.33)
Model 3 (adjusted)
f 1.34 (0.97–1.86) 0.98 (0.71–1.37)
Myocardial infarction
Model 1 (unadjusted) 131 6 8.6 386 18 8.8 0.97 1.02 (0.41–2.57) 0.58 (0.24–1.41)
Model 2 (adjusted)
b 1.13 (0.44–2.89) 0.63 (0.26–1.54)
Stroke
Model 1 (unadjusted) 133 2 2.7 398 2 0.9 0.28 0.35 (0.05–2.52) 0.19 (0.03–1.36)
Model 2 (adjusted)
b 0.82 (0.10–6.60) 0.30 (0.04–2.28)
Peripheral arterial disease
Model 1 (unadjusted) 101 51 119.3 307 134 99.3 0.29 0.84 (0.61–1.16) 0.74 (0.53–1.04)
Model 2 (adjusted)
b 0.97 (0.70–1.36) 0.80 (0.57–1.13)
Model 3 (adjusted)
g 1.13 (0.79–1.62) 0.89 (0.62–1.28)
Any macroangiopathy
Model 1 (unadjusted) 99 54 133.7 297 133 103.8 0.11 0.77 (0.56–1.06) 0.67 (0.48–0.93)
Model 2 (adjusted)
b 0.88 (0.63–1.21) 0.71 (0.51–0.99)
Model 3 (adjusted)
h 0.88 (0.63–1.22) 0.74 (0.52–1.04)
All vascular disease
Model 1 (unadjusted) 44 41 222.0 141 128 230.1 0.95 0.99 (0.69–1.41) 1.38 (0.89–2.15)
Model 2 (adjusted)
b 1.15 (0.80–1.64) 1.43 (0.91–2.23)
Model 3 (adjusted)
i ––
ROSSO endpoint
Model 1 (unadjusted) 110 8 13.8 328 26 15.3 0.76 1.13 (0.51–2.50) 0.54 (0.26–1.14)
Model 2 (adjusted)
b 1.29 (0.58–2.87) 0.58 (0.27–1.23)
aEvents per 1,000 person–years
bModel 2 includes age, sex and duration of diabetes in each case. Model 3 includes all variables in Model 2, plus:
cfasting plasma glucose
dAsian (negative), other European, mixed/other ethnicity (negative)
eBMI, ln[ACR], aspirin-use, any exercise in past 2 weeks (negative), married (negative)
fln[ACR]
gsystolic BP, aspirin-use, diabetes education (ever; negative), smoker, √daily alcohol consumption
hsystolic BP, aspirin-use, smoker, √daily alcohol consumption
inone after adjustment for
b
Diabetologia (2007) 50:510–515 513showed no significant benefit of baseline SMBG (p≥
0.11) for any endpoint, single or combination. Neither
adjustment for age, sex and diabetes duration (Model 2),
nor relevant additional variables independently associated
with the outcomes in Cox proportional hazards modelling
(Model 3), improved this result.
Time-dependent Cox models were included to allow for
commencement (or discontinuation) of SMBG during
follow-up. In both unadjusted and adjusted models, SMBG
during follow-up was associated with a reduction in the risk
of retinopathy of approximately 50%. In unadjusted
analysis, the risk of the development of any macrovascular
disease was reduced by 33% in patients who used SMBG,
but this became non-significant after full adjustment.
SMBG was not associated with the first occurrence of
the composite ROSSO endpoint (which occurred infre-
quently), either at baseline or as a time-dependent covariate.
Discussion
The present study represents the second observational
assessment of the relationship between SMBG and outcome
in type 2 diabetes. With regard to all-cause mortality in the
full FDS sample, our unadjusted data showed that baseline
SMBG was associated with a significant risk reduction, a
relationship observed in both non-insulin-treated and
insulin-treated subgroups. After adjustment for other
potential explanatory variables, this apparent benefit was
lost in both subgroups. For both combined micro- and
macroangiopathy outcomes, SMBG was not associated
with a first ever event in the 5-year longitudinal cohort in
either unadjusted or adjusted models, with or without time-
dependent analyses. These findings are inconsistent with
those of the ROSSO study [4], in which all-cause mortality
and diabetes-related morbidity were reduced by 32 and
51%, respectively, in patients employing SMBG.
What is the explanation for these discrepancies? ROSSO
had a larger number of patients than the FDS (3,268 vs
1,280), followed for a similar period. However, while the
FDS involved a prevalent, prospectively-studied, commu-
nity-based cohort and all patients had access to subsidised
SMBG [5], ROSSO was ‘retrolective’—newly-diagnosed
patients aged ≥45 years were selected—and only those
receiving insulin were reimbursed for SMBG [4]. Whereas
there was a low rate of migration of the FDS sample out of
Western Australia [9] (96% had been captured on the
WADLS by the end of June 2006 [10]), the retention rate of
the ROSSO primary care sample is unknown. The range of
potential explanatory variables (including diabetes educa-
tion, marital status, education, alcohol consumption, exer-
cise and urinary ACR) and the completeness of data
collection (e.g. HbA1c and serum HDL-cholesterol results
from a single laboratory were available for ≥98.8% of FDS
patients compared with only 45.5 and 30.2%, respectively,
from multiple laboratories in ROSSO [4]) were both much
greater in the FDS. The present analyses are therefore likely
to have assessed the independent contribution of SMBG to
diabetes-associated morbidity and mortality with greater
validity. A healthy survivor effect may also have confound-
ed the relationship between SMBG and non-fatal outcome
in ROSSO, while these analyses were undertaken in FDS
participants alive at the end of 5 years of follow-up.
After adjustment, SMBG was associated with an
increased risk of cardiac death in patients not treated with
insulin. Although the ROSSO investigators suggest that,
based on apparent benefits, SMBG may be a surrogate for
greater patient empowerment and physician interest, with
consequently improved compliance [4], it is equally
plausible that SMBG may represent a belated attempt to
improve glycaemic control by mostly non-insulin-treated
patients who become aware of symptoms of coronary
insufficiency and heart failure. Retinopathy was the only
non-fatal complication with which SMBG was indepen-
dently associated, with a significantly lower relative risk in
our 5-year cohort in both unadjusted and adjusted time-
dependent models. This could be a chance finding, but
could also reflect the effect of other variables not measured
in the FDS. It is not due to better glycaemic control in
patients who perform SMBG, since SMBG use did not
improve glycaemia [5]. The ROSSO study report does not
contain a similar disaggregated analysis [4].
The results of the present study do not support a
relationship between SMBG and improved survival in a
well-characterised community-based sample of type 2
diabetic patients. We found evidence that SMBG was
associated with an increased risk of cardiac death and a
reduced risk of retinopathy. These conflicting results might
reflect complex interactions between patient, physician and
disease factors in particular circumstances, but may also
represent the effects of confounding, incomplete covariate
adjustment or chance.
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